Navigation Links
In blood vessel stents, innovative materials allow better control, delivery of gene therapy
Date:4/15/2008

Before gene therapy becomes practical for treating human diseases, researchers must master the details of safe and effective delivery. Cardiology researchers at The Childrens Hospital of Philadelphia have advanced delivery techniques by creating a versatile synthetic material that can bind to a variety of gene therapy vectors and can be custom-designed for controlled local release of therapeutic genes at a disease site.

In an animal study, the research team used their new synthetic formulation to bind adenoviruses to bare metal stents, tiny metal scaffolds inside the carotid arteries of rats. Adenovirus served as a gene therapy vector to carry genes for an enzyme that significantly reduced restenosis, the hazardous narrowing of a blood vessel that often occurs despite the presence of a stent designed to hold it open.

Although the materials are in an early stage, the hope is that this method may help to treat artery disease in people. We developed a synthetic gene delivery system that can be used for any gene therapy vector, not just adenoviruses, said study leader Robert J. Levy, M.D., the William J. Rashkind Chair of Pediatric Cardiology at The Childrens Hospital of Philadelphia. Furthermore, this new formulation allows us to increase the dosage of gene therapy vectors delivered, and we can tune the materials for sustained release over a longer time period.

Levys group reported its study this week in the online version of the journal Circulation, published by the American Heart Association.

Over the past decade, stents have become increasingly useful in treating constricted blood vessels in heart disease and in peripheral artery disease. Stents, which expand partially blocked blood vessels to improve circulation, may be made of bare metal or may have a coating of polymers that release drugs.

Neither type is ideal. Polymer coatings cause inflammation in vessels, which may lead to new bottlenecks at the same time th
'/>"/>

Contact: John Ascenzi
Ascenzi@email.chop.edu
267-426-6055
Children's Hospital of Philadelphia
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Mediware Introduces Comprehensive Vision for Blood Center Technology
2. High Blood Pressure May Be Buffer Against Headaches
3. Potential blood test for chronic sinusitis identified
4. Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find
5. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
6. PATHFAST(R): Rapid Whole Blood Immunoassay Analyzer from Polymedco
7. Blood vessels: The pied piper for growing nerve cells
8. Cholesterol, blood pressure control may reverse atherosclerosis in adults with diabetes
9. Aggressive Cholesterol, Blood Pressure Treatment Shows Some Benefit
10. Microwave treatments for enlarged prostate cause blood pressure surges
11. Blood pressure enzyme can have tumor-sensing role
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)... HR Consulting firm CPEhr, and Junior Achi...hadow Day for 30 high-students from Downtown Busin...cs such as labor law, interviewing techniques and ...f. (PRWEB) July 24, 2008 -- Los Angeles HR Consul...ofit organization, hosted a Job Shadow Day for 30 ...
(Date:7/24/2008)... As America's baby boomers age, more ...s such as diabetes that necessitate the use of med...celet jewelry gives a generation attractive incent...n. , (PRWEB) July 24, 200...g health conditions can make a statement in more w...
(Date:7/23/2008)... N.Y., July 24 /PRNewswire/ -- MediVoice(R), LLC, ... for e-Health and,e-Prescribing, has formed a stra...ovider of interactive, web-based, patient-centered...on systems to integrate and market its,mobile voic...Care(TM),(VTOC) system., "MediVoice is pleased to...
(Date:7/23/2008)...roblem For 10+ Years Even Though Some Kilns Emit M...ement Kilns in AL, CA, IA,IL, MD, MI, MT, NY, OR,...e-USNewswire/ -- For more than a decade,after Cong...rom cement,kilns across the nation, the U.S. Envir...ction. Now, a new study from Earthjustice and the,...
Breaking Medicine News(10 mins):Health News:CPEhr and Junior Achievement Prepare High-School Students For the Workforce 2Health News:CPEhr and Junior Achievement Prepare High-School Students For the Workforce 3Health News:Aging Baby Boomers Meld Life-saving Data and Style with Lauren's Hope Fashion Medical ID Bracelet 2Health News:Aging Baby Boomers Meld Life-saving Data and Style with Lauren's Hope Fashion Medical ID Bracelet 3Health News:MediVoice(R) Partners With VisionTree(R) to Integrate Its Voice-Activated e-Prescribing Solution Into VisionTree's VTOC(TM) Web-Based Patient Management System 2Health News:MediVoice(R) Partners With VisionTree(R) to Integrate Its Voice-Activated e-Prescribing Solution Into VisionTree's VTOC(TM) Web-Based Patient Management System 3Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 2Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 3Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 4Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 5Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 6Health News:Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA 7
...that a migraine headache decreases over the years.... painful and do not last much long. These findin...he Society annual meeting in Chicago, by Carl Dahl...dical director and founder of the Gothenburg Migra...
...act that will be presented Monday at SLEEP 2007, a...d toddlers born prematurely occurs earlier than e...an among full-term infants. The study, authored b...f West Virginia University, consisted of the respo...
...gh, who was admitted to a hospital in East Delhi a...y raising speculations of a suicide attempt by hi... In a statement to the Delhi Police, Singh said th...e glass window panes broke when he banged his hand...
...worry about the ticking of their biological clocks...rugs that could delay menopause. The news was br...who told a press conference that researchers had f...uld be soon be developed into a pill or an injecti...
Other Medicine News:Health News:Ages Eases the Pain of Migraine 2Health News:Scientists Have Found Way to Delay Menopause 2
(Date:7/23/2008)...swire-FirstCall/ -- Dendreon Corporation,(Nasdaq: ...ndent Data,Monitoring Committee (IDMC) to review i...vival relating to the Company,s Phase 3 IMPACT (IM... also known as D9902B) clinical trial,of PROVENGE(...tigational,active cellular immunotherapy for the t...
(Date:7/22/2008)...RNewswire/ -- Nonin Medical, a leading innovator,o... 20 years, has entered,the clinical testing phase ...al oxygen saturation. Today,s most common applicat...ng of the regional blood oxygenation,in the brain ...comes from an ongoing clinical study at the,Duke U...
(Date:7/22/2008)...dy Confirms Tyrima Exhibits Excellent Drug-Like ...sults Support Initiation of Phase II Clinical Tria...wswire/ -- CeNeRx BioPharma,Inc., a clinical stag...e,treatments for diseases of the central nervous s...andidate Tyrima(TM) into Phase II trials for the,t...
(Date:7/22/2008)...th chemotherapy and pegylated enzyme produces s...erapy alone - - Pegylated enzyme ...FirstCall/ -- Halozyme Therapeutics,Inc. (Nasdaq:...nd,commercializing products targeting the extracel...positive pre-clinical animal efficacy data,for its...
Breaking Medicine Technology:Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 2Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 3Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 5Aflac and the American Association for Cancer Research Unite to Issue Inaugural Aflac Career Development Award for Childhood Cancer Research 4933 1Aflac and the American Association for Cancer Research Unite to Issue Inaugural Aflac Career Development Award for Childhood Cancer Research 4933 2Aflac and the American Association for Cancer Research Unite to Issue Inaugural Aflac Career Development Award for Childhood Cancer Research 4933 3Knowledge Based Reconstruction Demonstrates Accuracy in Obtaining Ventricular Volume and Function in Tetralogy of Fallot Patients According to Ventri 1921 1Knowledge Based Reconstruction Demonstrates Accuracy in Obtaining Ventricular Volume and Function in Tetralogy of Fallot Patients According to Ventri 1921 2Alexza Announces Positive Phase 1 Results With AZ 007 28Staccato 28R 29 Zaleplon 29 1919 1Alexza Announces Positive Phase 1 Results With AZ 007 28Staccato 28R 29 Zaleplon 29 1919 2Alexza Announces Positive Phase 1 Results With AZ 007 28Staccato 28R 29 Zaleplon 29 1919 3Alexza Announces Positive Phase 1 Results With AZ 007 28Staccato 28R 29 Zaleplon 29 1919 4Measurements Poor for Assessing Clinical Trials With Children 17915 1Measurements Poor for Assessing Clinical Trials With Children 17915 2
....H.--(BUSINESS WIRE)--May 24, 2007 - Bentley,Pharm...utical,company, today announced that a late breaki...pted for a poster presentation at the,American Dia...ago.,The abstract, entitled "Results of a Randomiz...y of Intranasal Insulin Spray,(Nasulin(TM)) and In...
...O, May 23, 2007 /PRNewswire-FirstCall/ -- Shire pl...of the,investigational medication guanfacine exten...), a selective,alpha-2A-adrenoceptor agonist. Thes...olled studies and two long-term phase III,open-lab...tric,Association (APA) annual meeting, demonstrate...
Other Medicine Technology:Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions 2Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions 3Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 2Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 3Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 4Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 5Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 6Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 7Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 8
...nts incorporate a layered design unique in the ind...to prevent stray electrosurgical burns along the s...e or capacitive coupling; a well-documented patien...l AEM Instruments provides a neutral return path f...
...nts incorporate a layered design unique in the ind...to prevent stray electrosurgical burns along the s...e or capacitive coupling; a well-documented patien...l AEM Instruments provides a neutral return path f...
...nts incorporate a layered design unique in the ind...to prevent stray electrosurgical burns along the s...e or capacitive coupling; a well-documented patien...l AEM Instruments provides a neutral return path f...
...nts incorporate a layered design unique in the ind...to prevent stray electrosurgical burns along the s...e or capacitive coupling; a well-documented patien...l AEM Instruments provides a neutral return path f...
Medicine Products: